Journal: Frontiers in Immunology
Article Title: Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19
doi: 10.3389/fimmu.2021.716361
Figure Lengend Snippet: Comparison of plasma markers of endothelial cell dysfunction (ICAM 1, Thrombomodulin, P-Selectin). (A) shows results for patients with positive (+) or negative (-) COVID-19 PCR test results. (B) further stratifies results based on low (<1.0 ug/ml FEU) or high (>1.0 ug/ml FEU) D-dimer concentration. Numerical results are summarized in (C) .
Article Snippet: Selected biomarkers of endothelial cell dysfunction, including ICAM-1 (Quantikine ELISA, Human ICAM-1/CD54 -specific immunoassay, R&D Systems, Inc., Minneapolis, MN), and thrombomodulin (Quantikine ELISA, Human Thrombomodulin/BDCA-3 immunoassay, R&D Systems, Inc., Minneapolis, MN), as well as platelet and endothelial cell activation, P-selectin (Quantikine ELISA, Human P-Selectin/CD62P immunoassay, R&D Systems, Inc., Minneapolis, MN), were evaluated.
Techniques: Comparison, Clinical Proteomics, Concentration Assay